All In Biotech

Drug Trial Radar · NCT04890873

ERX1000 - Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Male and Female Subjects With Obesity

ERX1000 - A Phase I, Double-blind, Placebo-controlled, Single and Multiple Oral Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Male and Female Subjects With Obesity

Last checked: Nov 19, 2026Latest source record: Oct 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

48

Actual

Start

Oct 17, 2019

Primary completion

Jul 3, 2023

Study completion Jul 3, 2023

Sponsor

Lead sponsor
ERX PharmaceuticalsIndustry
Sponsor type
Industry
First posted
May 18, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective is to assess the safety and tolerability of single and multiple oral doses of ERX1000 in obese subjects.

Conditions

  • Obesity

Interventions

  • ERX1000Drug

    ERX1000 powder provided for preparation of a 4 mg/10 mL oral suspension and 8 mg/10 mL oral suspension

  • PlaceboDrug

    A suspension containing magnesium hydroxide carbonate in polysorbate

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A (Single Dose Group A9): Incidence and severity of adverse events (AEs)Time frame: Day 1 up to end of study (Day 10)
  2. Part A (Single Dose Group A9): Incidence of clinical laboratory abnormalitiesTime frame: Screening (Day -28) up to end of study (Day 10)
  3. Part A (Single Dose Group A9): Incidence of 12-lead electrocardiogram (ECG) abnormalitiesTime frame: Screening (Day -28 to Day -2), Days 1, 3 and 10
  4. Part A (Single Dose Group A9): Incidence of vital sign abnormalitiesTime frame: Screening (Day -28 to Day -2), Check-in (Day -1), Days 1, 3, 4, 5, 6 and 10
  5. Part A (Single Dose Group A9): Incidence of physical examination abnormalitiesTime frame: Check-in (Day -1), Days 6 and 10
  6. Part B (Multiple Dose Group B5): Incidence of 12-lead electrocardiogram (ECG) abnormalitiesTime frame: Screening (Day -28 to Day -3), Check-in (Day -2), Days 1, 4, 7, 10, 19, 25, 28, 30 and 37
  7. Part B (Multiple Dose Group B5): Incidence of vital sign abnormalitiesTime frame: Screening (Day -28 to Day -3), Check-in (Day -2), Days 1, 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, 15, 16, 19, 22, 25, 28, 30 and 37
  8. Part B (Multiple Dose Group B5): Incidence of physical examination abnormalitiesTime frame: Check-in (Day -2), Days 30, 33 and 37
  9. Part B (Multiple Dose Group B6): Incidence of 12-lead electrocardiogram (ECG) abnormalitiesTime frame: Screening (Day -28 to Day -3), Check-in (Day -2), Days 1, 3, 8, 10, 15, 17, 22, 25, 29, 34 and End of Study (Day 41)
  10. Part B (Multiple Dose Group B6): Incidence of vital sign abnormalitiesTime frame: Screening (Day -28 to Day -3), Check-in (Day -2), Days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 25, 27, 29, 34, 38 and End of Study (Day 41)
  11. Part B (Multiple Dose Group B6): Incidence of physical examination abnormalitiesTime frame: Check-in (Day -2), Days 34, 38 and End of Study (Day 41)
  12. Part B (Multiple Dose Group B5 and Multiple Dose Group B6): Incidence and severity of adverse events (AEs)Time frame: Day 1 up to end of study (For Group B5, Day 37 and for Group B6, Day 41)
  13. Part B (Multiple Dose Group B5 and Multiple Dose Group B6): Incidence of clinical laboratory abnormalitiesTime frame: Screening (Day -28), Check-in (Day-2), Days 7, 14, 21, 28, 34 and End of Study (Day 41)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Labcorp Clinical Research Unit Inc.

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.